Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy – StreetInsider.com
|
Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy
StreetInsider.com Analyst Madhu Kumar commented, "We initiate coverage of CRISPR Therapeutics (CRSP, or CRISPR Tx) with a Buy rating (PT $23.50), on our view of possible upside on clinical leadership in CRISPR therapy overriding the risk of possible downside on the … |
